Evidence map›Paper›PMID 42681674›Full record

Observational studyClinical and translational science2026

An Observational Study of the Effect of Concomitant Levetiracetam on Apixaban Concentrations in a Hospital Cohort.

Chazmyn Riley, Kevin Lam, Cristina Micale, Lynda Thomson, Douglas F Stickle, Walter K Kraft

Abstract readObservational Study
In one paragraph

Observational study in Clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chazmyn RileyDepartment of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0009-0008-6435-7611
Kevin LamDepartment of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0001-9838-613X
Cristina MicaleSidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Lynda ThomsonDepartment of Pharmacy, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA.
Douglas F StickleDepartment of Pathology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-2033-4943
Walter K KraftDepartment of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-5074-0141

Funding

CLINICAL PHARMACOLOGY TRAINING PROGRAMT32GM008562 · NIGMS · THOMAS JEFFERSON UNIVERSITY · PI WALTER K KRAFT, Scott A. Waldman · 1995 to 2026
$10.2M
NIGMS NIH HHS T32 GM008562NIH HHS T32GM008562
6 · The paper itself

Abstract

Despite the lack of evidence of a mechanism-based drug interaction, some professional organizations have advised caution coadministering apixaban and levetiracetam. Eligible patients taking apixaban with or without levetiracetam for any indication for at least 72 h were screened from the electronic medical records. Plasma samples from 77 patients were retrieved from salvaged clinical blood collections. Apixaban minimum and maximum concentrations (C

Indexed as

Factor Xa InhibitorsLevetiracetamPyrazolesPyridonesAgedAged, 80 and overDrug InteractionsDrug Therapy, CombinationFemaleHumansMaleMiddle AgedapixabanFactor Xa InhibitorsLevetiracetamPyrazolesPyridonesapixabandrug–drug interactionlevetiracetamnon‐valvular atrial fibrillationpharmacokinetics

Identifiers

PMID42681674
PMCPMC13534558

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.